Penciclovir
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Penciclovir: From Herpesvirus Infection to Fascioliasis
One-Sentence Summary
Penciclovir is a nucleoside analogue antiviral whose known pharmacology targets herpesvirus (HSV-1/2, VZV) DNA polymerase. The TxGNN model predicts it may be effective for Fascioliasis (liver fluke infection), but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on knowledge-graph similarity alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Herpesvirus infections (HSV-1/2, VZV) — inferred from mechanism; no formal indication record in evidence pack |
| Predicted New Indication | Fascioliasis |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L5 |
| Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Penciclovir is a guanosine nucleoside analogue. After phosphorylation by viral/host kinases, it inhibits herpesvirus DNA polymerase, and its pharmacology is specific to viral replication within the Herpesviridae family (HSV-1/2, VZV).
Fascioliasis is a trematode (fluke) infection caused by Fasciola hepatica, whose pathogenic mechanism involves helminth metabolic enzymes (e.g., glutathione S-transferase, proteases) and host immune response — a biological pathway that shares no known overlap or analogy with viral DNA polymerase inhibition.
Based on the available evidence, this prediction does not have a credible mechanistic basis. It most likely reflects a high similarity score generated by TxGNN’s knowledge-graph embedding rather than genuine pharmacological plausibility. The absence of the drug’s formal original-indication data further weakens confidence in this mechanistic inference.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No marketing authorization records are available in this evidence pack. Penciclovir currently holds 0 licenses and its market status is Not Marketed.
Safety Considerations
Please refer to the package insert for safety information.
Note: Structured TFDA warning/contraindication data and full mechanism-of-action data for this candidate are currently missing (see Data Gaps below), which blocks formal safety (S1) evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is no clinical trial or literature evidence, and the proposed mechanistic link between herpesvirus DNA polymerase inhibition and trematode (liver fluke) infection is biologically implausible. This is a model-prediction-only (L5) candidate with no independent supporting evidence.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a blocking data gap)
- Confirmed mechanism of action (currently a high-severity data gap)
- Preclinical or in vitro evidence of penciclovir activity against Fasciola hepatica or related trematodes
- Any pharmacological rationale connecting nucleoside analogues to anthelmintic activity, if one exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.